Stockscreener 앱 받기
72.49
1.39%
-1.01
Astrazeneca PLC 주식(AZN)의 최신 뉴스
AstraZeneca reports total voting rights - Investing.com
Peering Into AstraZeneca's Recent Short Interest - Benzinga
Baxdrostat, AstraZeneca’s Next Big CVRM Bet - insights.citeline.com
AstraZeneca Announces Share Capital and Voting Rights Update - TipRanks
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication - Yahoo
428,441 Shares in AstraZeneca PLC (NASDAQ:AZN) Purchased by Brandywine Global Investment Management LLC - MarketBeat
A £10,000 investment in AstraZeneca shares last Christmas is now worth… - Fool UK
AstraZeneca: 'AZD0780' promising against cholesterol - MarketScreener
AstraZeneca’s (AZN LN) Potential Blockbuster Pill Halves High Cholesterol - Bloomberg.com
Congress Wealth Management LLC DE Raises Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients - AOL.com
AstraZeneca Says Investigational Drug Cuts LDL Cholesterol in Phase 2b Trial - MarketScreener
AstraZeneca reports cholesterol drug success in trial By Investing.com - Investing.com UK
AstraZeneca Oral PCSK9 Prospects Pumped After Phase IIb Win - insights.citeline.com
AstraZeneca’s Calquence Nears EU Approval for Mantle Cell Lymphoma - Investing.com
AstraZeneca's Muscle-Invasive Bladder Cancer Treatment Gets FDA Approval - MarketScreener
Astrazeneca Receives Approval Recommendation for Calquence Combination Therapy in Europe - MarketScreener
FDA approves AstraZeneca’s Imfinzi for bladder cancer - Investing.com
FDA approves AstraZeneca’s Imfinzi for bladder cancer By Investing.com - Investing.com UK
FDA approves AstraZeneca’s IMFINZI for bladder cancer By Investing.com - Investing.com UK
AstraZeneca makes regulatory progress with Imfinzi, Calquence - ShareCast
AstraZeneca Scores Key Regulatory Wins in US, EU for Cancer Treatments - Marketscreener.com
AstraZeneca PLC : A technical turn-around configuration - MarketScreener
AstraZeneca's Calquence Combo Gets Positive Opinion from EU Panel for Rare Blood Cancer - Marketscreener.com
Astrazeneca's Calquence Recommended For EU Approval In 1L MCL - Marketscreener.com
AstraZeneca’s Imfinzi granted FDA approval in the US for bladder cancer - DirectorsTalk Interviews
Imfinzi by AstraZeneca gets US approval for bladder cancer treatment - Investing.com UK
J&J Passes AstraZeneca in Lung Cancer Drug Race — For Now - MSN
SFJ Pharmaceuticals & SERB Pharmaceuticals Present Positive Final Results from Pivotal Ph 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Surgery or Experiencing Major Bleeding - GlobeNewswire Inc.
AstraZeneca Pharma India to discontinue manufacturing, marketing of angina drug from April 1 - Medical Dialogues
AstraZeneca's Imfinzi gains additional indication for bladder cancer - Seeking Alpha
AstraZeneca (AZN) Gains FDA Approval for New Imfinzi Indication - GuruFocus
Is AstraZeneca (AZN) the Best ADR Stock to Buy According to Hedge Funds? - Yahoo Finance
AstraZeneca PLC ADR outperforms competitors on strong trading day - MarketWatch
AstraZeneca Sues Consultancy For £32M Over HQ Defects - Law360
Goldman Sachs maintains AstraZeneca stock with $98 target By Investing.com - Investing.com UK
Goldman Sachs lifts AstraZeneca stock target, sees growth By Investing.com - Investing.com UK
AstraZeneca Fights Generic Diabetes Drug Launch - Law360
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga
Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet - Yahoo Finance
Berenberg Keeps AstraZeneca at Buy on Pipeline Potential - Marketscreener.com
Del. Justices Back Axing Suit Over $3B AstraZeneca Viela Sale - Law360
J&J passes AstraZeneca in lung cancer drug race — for now - Crain's New York Business
J&J’s Rybrevant-Lazcluze Combo Tops AstraZeneca’s Drug in EGFR Lung CancerJohnson & Johnson (NYSE:JNJ) - Benzinga
J&J Passes AstraZeneca in Blockbuster Cancer Race — For Now - Bloomberg
AstraZeneca's Win in Shareholder Suit Over Viela Sale Affirmed - Bloomberg Law News
China on track to outpace Europe in pharmaceutical innovation, says AstraZeneca CEO By Investing.com - Investing.com South Africa
China on track to outpace Europe in pharmaceutical innovation, says AstraZeneca CEO - Investing.com India
Europe Rapidly Falling Behind China in Pharma, AstraZeneca CEO Warns - Bloomberg
Whittier Trust Co. Boosts Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Astrazeneca invests in China: $8B in deals, $2.5B in R&D center - BioWorld MedTech
Astrazeneca Says Tagrisso Shows Improved Overall Survival Trend In Laura Phase 3 Trial - MarketScreener
AstraZeneca Seeks to Move Past China Probe With R&D Hub - Bloomberg
AstraZeneca seeks to move past China probe with Beijing R&D hub - The Edge Malaysia
AstraZeneca PLC ADR underperforms Monday when compared to competitors - MarketWatch
Assemblin to upgrade AstraZeneca’s Gärtuna plant in Sweden - Yahoo Finance
AstraZeneca and GKS shares have legs, but the weight loss titans will dominate, says investment bank - Proactive Investors
Prediction: 12 months from now, AstraZeneca’s share price could be… - Yahoo
AstraZeneca to invest $2.5bn in R&D centre in China - Pharmaceutical Technology
Assemblin Caverion Group Unit to Upgrade AstraZeneca's Swedish Plant -March 24, 2025 at 03:37 am EDT - MarketScreener
Top global stories of the week: AstraZeneca, BYD, SoftBank among notable names - Seeking Alpha
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
AstraZeneca Expands Emphasis On China, Already A Key Market - Citeline
자본화:
|
볼륨(24시간):